利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.025 秒)

    Pharmaceutical compositions comprising a polynucleotide and optionally an antigen especially for vaccination
    1.
    发明申请
    Pharmaceutical compositions comprising a polynucleotide and optionally an antigen especially for vaccination 审中-公开
    包含多核苷酸和任选的抗原的药物组合物，尤其用于疫苗接种

    公开(公告)号：US20090060927A1

    公开(公告)日：2009-03-05

    申请号：US10811226

    申请日：2004-03-26

    申请人： Hermann Wagner ,  Grayson Lipford ,  Klaus Heeg

    发明人： Hermann Wagner ,  Grayson Lipford ,  Klaus Heeg

    IPC分类号： A61K39/00

    CPC分类号： A61K39/39 ,  A61K2039/55561 ,  Y02A50/41

    摘要： The present invention relates to pharmaceutical compositions comprising at least one fragment of a polynucleotide, preferably at least one antigen, and optionally a pharmaceutically acceptable carrier and/or diluent. In accordance with the present invention was found that the introduction of the pharmaceutical composition into vertebrates will achieve regulation of growth, induction of cellular transcription and translation, protein synthesis, protein expression or protein secretion. The pharmaceutical compositions are useful in vaccination protocols but also in any other therapeutic situation in which immunomodulation is of benefit, such as sub-optimal immune responses, reaction to pathogens, tolerance or autoimmunity.

    摘要翻译： 本发明涉及包含多核苷酸的至少一个片段，优选至少一种抗原和任选的药学上可接受的载体和/或稀释剂的药物组合物。 发现根据本发明，将药物组合物引入脊椎动物将实现生长调节，诱导细胞转录和翻译，蛋白质合成，蛋白质表达或蛋白质分泌。 药物组合物可用于疫苗接种方案，但也可用于免疫调节有益的任何其它治疗情况，例如亚最佳免疫应答，对病原体的反应，耐受性或自身免疫性。

    Pharmaceutical composition comprising a polynucleotide and optionally an antigen especially for vaccination
    2.
    发明申请
    Pharmaceutical composition comprising a polynucleotide and optionally an antigen especially for vaccination 审中-公开
    包含多核苷酸和任选的抗原的药物组合物，特别是用于疫苗接种

    公开(公告)号：US20050054601A1

    公开(公告)日：2005-03-10

    申请号：US10894655

    申请日：2004-07-16

    申请人： Hermann Wagner ,  Grayson Lipford ,  Klaus Heeg

    发明人： Hermann Wagner ,  Grayson Lipford ,  Klaus Heeg

    IPC分类号： C12N15/09 ,  A61K31/7088 ,  A61K39/00 ,  A61K39/39 ,  A61K48/00 ,  A61P37/04 ,  C07K14/195 ,  C07K14/435

    CPC分类号： A61K39/39 ,  A61K2039/55561 ,  Y02A50/41

    摘要： The present invention relates to pharmaceutical compositions comprising at least one fragment of a polynucleotide, preferably at least one antigen, and optionally a pharmaceutically acceptable carrier and/or diluent. In accordance with the present invention was found that the introduction of the pharmaceutical composition into vertebrates will achieve regulation of growth, induction of cellular transcription and translation, protein synthesis, protein expression or protein secretion. The pharmaceutical compositions are useful in vaccination protocols but also in any other therapeutic situation in which immunomodulation is of benefit, such as sub-optimal immune responses, reaction to pathogens, tolerance or autoimmunity.

    摘要翻译： 本发明涉及包含多核苷酸的至少一个片段，优选至少一种抗原和任选的药学上可接受的载体和/或稀释剂的药物组合物。 发现根据本发明，将药物组合物引入脊椎动物将实现生长的调节，细胞转录和翻译的诱导，蛋白质合成，蛋白质表达或蛋白质分泌。 药物组合物可用于疫苗接种方案，但也可用于免疫调节有益的任何其它治疗情况，例如亚最佳免疫应答，对病原体的反应，耐受性或自身免疫性。

    Nucleic acids for high throughput screening of CpG-based immuno-agonist/antagonist
    4.
    发明授权
    Nucleic acids for high throughput screening of CpG-based immuno-agonist/antagonist 失效
    用于高通量筛选基于CpG的免疫激动剂/拮抗剂的核酸

    公开(公告)号：US06943240B2

    公开(公告)日：2005-09-13

    申请号：US09954987

    申请日：2001-09-17

    申请人： Stefan Bauer ,  Grayson Lipford ,  Hermann Wagner

    发明人： Stefan Bauer ,  Grayson Lipford ,  Hermann Wagner

    IPC分类号： G01N33/50 ,  A61K45/00 ,  A61K48/00 ,  A61P37/00 ,  C07K14/705 ,  C07K16/28 ,  C07K19/00 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/12 ,  C12Q1/02 ,  C12Q1/68 ,  G01N27/447 ,  G01N33/15 ,  G01N33/53 ,  G01N33/566 ,  C07H21/00

    CPC分类号： C07K14/705

    摘要： The invention pertains to murine TLR9 and related TLR9s which include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically functional variants of the murine TLR9. The invention further relates to methods of using such murine and non-murine TLR9 nucleic acids and polypeptides, especially in methods for screening for agonists and antagonists of immunostimulatory CpG nucleic acids. Also included are murine TLR9 inhibitors which inhibit murine TLR9 activity by inhibiting the expression or function of murine TLR9. In a further aspect the present invention pertains to murine TLR7 and murine TLR8, as well as related TLR7 and TLR8 molecules which include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically functional variants of the murine TLR7 and TLR8. Methods are included for screening for ligands of TLR7 and TLR8, as well as for inhibitors and agonists and antagonists of signaling mediated by TLR7 and TLR8.

    摘要翻译： 本发明涉及鼠TLR9和相关TLR9，其包括鼠特异性氨基酸，以及编码这些多肽的核酸。 本发明还包括鼠TLR9的片段和生物学功能变体。 本发明还涉及使用这种鼠和非鼠TLR9核酸和多肽的方法，特别是用于筛选免疫刺激性CpG核酸的激动剂和拮抗剂的方法。 还包括通过抑制鼠TLR9的表达或功能来抑制鼠TLR9活性的鼠TLR9抑制剂。 在另一方面，本发明涉及鼠TLR7和鼠TLR8，以及包括鼠特异性氨基酸的相关TLR7和TLR8分子，以及编码那些多肽的核酸。 本发明还包括鼠TLR7和TLR8的片段和生物功能变体。 包括用于筛选TLR7和TLR8配体的方法，以及由TLR7和TLR8介导的抑制剂和激动剂和信号通路拮抗剂。

    Process for high throughput screening of CpG-based immuno-agonist/antagonist
    5.
    发明申请
    Process for high throughput screening of CpG-based immuno-agonist/antagonist 失效
    基于CpG的免疫激动剂/拮抗剂的高通量筛选方法

    公开(公告)号：US20050181422A1

    公开(公告)日：2005-08-18

    申请号：US11084777

    申请日：2005-03-18

    申请人： Stefan Bauer ,  Grayson Lipford ,  Hermann Wagner

    发明人： Stefan Bauer ,  Grayson Lipford ,  Hermann Wagner

    IPC分类号： G01N33/50 ,  A61K45/00 ,  A61K48/00 ,  A61P37/00 ,  C07K14/705 ,  C07K16/28 ,  C07K19/00 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/12 ,  C12Q1/02 ,  C12Q1/68 ,  G01N27/447 ,  G01N33/15 ,  G01N33/53 ,  G01N33/566

    CPC分类号： C07K14/705

    摘要： The invention pertains to murine TLR9 and related TLR9s which include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically functional variants of the murine TLR9. The invention further relates to methods of using such murine and non-murine TLR9 nucleic acids and polypeptides, especially in methods for screening for agonists and antagonists of immunostimulatory CpG nucleic acids. Also included are murine TLR9 inhibitors which inhibit murine TLR9 activity by inhibiting the expression or function of murine TLR9. In a further aspect the present invention pertains to murine TLR7 and murine TLR8, as well as related TLR7 and TLR8 molecules which include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically functional variants of the murine TLR7 and TLR8. Methods are included for screening for ligands of TLR7 and TLR8, as well as for inhibitors and agonists and antagonists of signaling mediated by TLR7 and TLR8.

    摘要翻译： 本发明涉及鼠TLR9和相关TLR9，其包括鼠特异性氨基酸，以及编码这些多肽的核酸。 本发明还包括鼠TLR9的片段和生物学功能变体。 本发明还涉及使用这种鼠和非鼠TLR9核酸和多肽的方法，特别是用于筛选免疫刺激性CpG核酸的激动剂和拮抗剂的方法。 还包括通过抑制鼠TLR9的表达或功能来抑制鼠TLR9活性的鼠TLR9抑制剂。 在另一方面，本发明涉及鼠TLR7和鼠TLR8，以及包括鼠特异性氨基酸的相关TLR7和TLR8分子，以及编码那些多肽的核酸。 本发明还包括鼠TLR7和TLR8的片段和生物功能变体。 包括用于筛选TLR7和TLR8配体的方法，以及由TLR7和TLR8介导的抑制剂和激动剂和信号通路拮抗剂。

    Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
    9.
    发明申请
    Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling 审中-公开
    用于鉴定影响toll样受体9（TLR9）信号传导的化合物的无细胞方法

    公开(公告)号：US20050100983A1

    公开(公告)日：2005-05-12

    申请号：US10982193

    申请日：2004-11-05

    申请人： Stefan Bauer ,  Grayson Lipford ,  Hermann Wagner ,  Mark Rutz

    发明人： Stefan Bauer ,  Grayson Lipford ,  Hermann Wagner ,  Mark Rutz

    IPC分类号： C07K14/705 ,  G01N33/566 ,  C12P21/06

    CPC分类号： C07K14/705 ,  C07K2319/30 ,  G01N33/566 ,  G01N2500/02

    摘要： The invention is directed to methods for screening for a compound that affects interaction between a Toll-like receptor (TLR) and a ligand for the TLR. The methods involve direct measurement of interaction using, for example, surface plasmon resonance (SPR), particularly under conditions of pH that mimic those of the TLR in vivo. Compounds identified using the methods of the invention may be useful in the development of agents useful in the treatment of conditions characterized by undesirable immune activation, e.g., autoimmunity, inflammation, allergy, asthma, and transplantation.

    摘要翻译： 本发明涉及筛选影响Toll样受体（TLR）与TLR配体之间相互作用的化合物的方法。 所述方法包括使用例如表面等离子体共振（SPR）直接测量相互作用，特别是在体内与模拟TLR的pH的条件下。 使用本发明的方法鉴定的化合物可用于开发可用于治疗特征在于不期望的免疫激活（例如自身免疫，炎症，过敏，哮喘和移植）的病症的药剂。